Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
PYLORI-CHEK BREATH TEST is a non-invasive diagnostic agent using carbon-13 labeled urea to detect Helicobacter pylori infection via breath analysis. Patients ingest the oral solution, and if H. pylori is present, the bacteria metabolize the labeled urea, releasing carbon-13 dioxide that is measured in exhaled breath. This is a diagnostic tool rather than a therapeutic drug.
As a diagnostic agent approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on defending market position in a commoditizing segment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PYLORI-CHEK offers exposure to the diagnostic business model and formulary/payer negotiations but limited career growth due to approaching LOE and minimal linked job opportunities (0). Career value is best realized by professionals seeking operational excellence, managed care expertise, or portfolio defense experience in a maturing asset.
Worked on PYLORI-CHEK BREATH TEST at GT Metabolic Solutions? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.